Polio Research Today is a free monthly online journal that collates and summarizes the latest research about Polio, including details on symptoms, treatment, vaccines, causes, virus.

Outbreak of poliomyelitis in Finland in 1984-85 - Re-analysis of viral sequences using the current standard approach.

Simonen ML, Roivainen M, Iber J, Burns C, Hovi T

Gastrointestinal Infections Unit, Department of Infectious Disease Surveillance and Control, Division of Health Protection, National Institute for Health and Welfare (THL), P.O. Box 30, FI-00271 Helsinki, Finland.

In 1984, a wild type 3 poliovirus (PV3/FIN84) spread all over Finland causing nine cases of paralytic poliomyelitis and one case of aseptic meningitis. The outbreak was ended in 1985 with an intensive vaccination campaign. By limited sequence comparison with previously isolated PV3 strains, closest relatives of PV3/FIN84 were found among strains circulating in the Mediterranean region. Now we wanted to reanalyse the relationships using approaches currently exploited in poliovirus surveillance. Cell lysates of 22 strains isolated during the outbreak and stored frozen were subjected to RT-PCR amplification in three genomic regions without prior subculture. Sequences of the entire VP1 coding region, 150 nucleotides in the VP1-2A junction, most of the 5' non-coding region, partial sequences of the 3D RNA polymerase coding region and partial 3' non-coding region were compared within the outbreak and with sequences available in data banks. In addition, complete nucleotide sequences were obtained for 2 strains isolated from two different cases of disease during the outbreak. The results confirmed the previously described wide intraepidemic variation of the strains, including amino acid substitutions in antigenic sites, as well as the likely Mediterranean region origin of the strains. Simplot and bootscanning analyses of the complete genomes indicated complicated evolutionary history of the non-capsid coding regions of the genome suggesting several recombinations with different HEV-C viruses in the past.

Published 9 December 2009 in Virus Res, 147(1): 91-7.
Full-text of this article is available online (may require subscription).

Articles on Polio published 2 November 2009:

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.   Vaccine, 27(47): 6558-63.

Poliovirus transmission is controlled globally through world-wide use of a live attenuated oral polio vaccine (OPV). However, the imminence of global poliovirus eradication calls for a switch to the inactivated polio vaccine (IPV). Given the limited manufacturing capacity and high cost of IPV, this switch is unlikely in most developing and undeveloped countries. Adjuvantation is an effective strategy for antigen sparing. In this study, we evaluated the adjuvanticity of CpG oligodeoxynucleotides ... [Abstract] [Full-text]

Articles on Polio published 16 October 2009:

Changes in ability, perceived difficulty and use of assistive devices in everyday life: a 4-year follow-up study in people with late effects of polio.   Acta Neurol Scand, 120(5): 324-30.

BACKGROUND: There are numbers of persons living in the community with late effects of polio, of which many develop new symptoms, but the course of progression is unclear. OBJECTIVES: To assess changes after 4 years in ability and perceived difficulty in persons with late effects of polio. MATERIAL AND METHODS: Community dwelling persons from a polio clinic. Information was gathered by questionnaire and interview on demographics, age at polio onset, affected body parts, health problems, the use ... [Abstract] [Full-text]

Articles on Polio published 14 October 2009:

An evaluation of the sensitivity of acute flaccid paralysis surveillance for poliovirus infection in Australia.   BMC Infect Dis, 9: 162.

BACKGROUND: World Health Organization (WHO) targets for acute flaccid paralysis (AFP) surveillance, including the notification of a minimum rate of AFP among children, are used to assess the adequacy of AFP surveillance for the detection of poliovirus infection. Sensitive surveillance for poliovirus infection in both developed and developing countries is essential to support global disease eradication efforts. We applied recently developed methods for the quantitative evaluation of disease ... [Abstract] [Full-text]

Articles on Polio published 1 September 2009:

Post-polio syndrome: epidemiologic and prognostic aspects in Brazil.   Acta Neurol Scand, 120(3): 191-7.

OBJECTIVES: To describe the clinical and epidemiological aspects of post-polio syndrome (PPS) and identify predictors of its severity. MATERIALS AND METHODS: 132 patients with PPS were selected at the Neuromuscular Disease Outpatient Clinic of the Federal University of São Paulo. Descriptive analysis was carried out and predictors of PPS severe forms were investigated using an unconditional logistic regression. RESULTS: The average age at onset was 39.4 years. The most common symptoms were ... [Abstract] [Full-text]

Articles on Polio published 17 August 2009:

Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program.   Vaccine, 27(39): 5293-4.

In this article, we will present an update about current status of inactivated poliovirus vaccine (IPV) and we will also discuss general concerns about inactivated polio vaccine (IPV) which are under discussion in scientific community about various aspects of IPV and at the end of this article, we will give our conclusions about possible universal use of IPV. [Abstract] [Full-text]

A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children.   Vaccine, 27(40): 5472-9.

Live attenuated influenza vaccine (LAIV) provides a useful tool to rapidly immunize populations in the developing world to prevent influenza outbreaks. In this noninferiority trial conducted in Asia and South America, where oral poliovirus vaccine (OPV) is still used, 2503 children aged 6 to <36 months with three polio immunizations were randomized to receive LAIV+OPV, placebo+OPV, or LAIV only. Immune responses in children receiving concomitant LAIV+OPV were noninferior to those observed in ... [Abstract] [Full-text]

Articles on Polio published 28 July 2009:

Three cases of paralytic poliomyelitis associated with type 3 vaccine poliovirus strains in Bulgaria.   J Med Virol, 81(9): 1661-7.

Oral poliovirus vaccine (OPV) can cause, in extremely rare cases vaccine-associated paralytic poliomyelitis in recipients, or contacts of vaccinees. Three cases of vaccine-associated paralytic poliomyelitis (two contacts and one recipient) occurred in the Bourgas region of Bulgaria in the spring of 2006. The first two cases, notified as acute flaccid paralysis, were 55 days old unvaccinated twin brothers, having been in contact with vaccinees. The third case concerned a 4-month-old infant who ... [Abstract] [Full-text]

Articles on Polio published 16 June 2009:

A tale of two global health programs. Smallpox eradication's lessons for the antipolio campaign in India.   Am J Public Health, 99(7): 1176-84.

India provided one of the most challenging chapters of the worldwide smallpox eradication program. The campaign was converted from a project in which a handful of officials tried to impose their ideas on a complex health bureaucracy to one in which its components were constantly adapted to the requirements of a variety of social, political, and economic contexts. This change, achieved mainly through the active participation of workers drawn from local communities in the 1970s, proved to be a ... [Abstract] [Full-text]

© 2004-2010 Polio Research Today. All Rights Reserved.